{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:26:28Z","timestamp":1759742788360},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mass vaccination against coronavirus disease 2019 (COVID-19) is ongoing in many countries worldwide. This study reports the occurrence of acute adverse events among vaccine recipients at a mass vaccination center in Japan. Between August and November 2021, approximately 130,000 individuals received two mRNA vaccine doses (mRNA-1273; Moderna) at the vaccination center. Acute adverse events at the site were observed in 1.1% of the recipients after the first dose and in 0.4% of the recipients after the second dose. The most common event was vasovagal syncope\/presyncope, followed by acute allergic reactions. The occurrence rate of vasovagal syncope\/presyncope was highest in the young population of those aged 16\u201329\u00a0years, but such age-dependency was not apparent in acute allergic reactions. Both symptoms were more prevalent in women than in men. Vasovagal syncope\/presyncope occurred mainly within 20\u00a0min of the injection, whereas nearly half of the episodes of acute allergic reactions occurred after 20\u00a0min. The vaccine being injected while the recipient was in the supine position effectively reduced the occurrence of vasovagal syncope\/presyncope. In summary, the suggested risk factors for vasovagal syncope\/presyncope included a young age and female sex. The vaccine being injected while the recipient was in the supine position would reduce the risk of vasovagal syncope\/presyncope.<\/jats:p>","DOI":"10.1038\/s41598-022-19936-5","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:07:47Z","timestamp":1663243667000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Reports of acute adverse events in mRNA COVID-19 vaccine recipients after the first and second doses in Japan"],"prefix":"10.1038","volume":"12","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamotsu","family":"Onodera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Harigae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"issue":"10278","key":"19936_CR1","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","volume":"397","author":"A Fontanet","year":"2021","unstructured":"Fontanet, A. et al. SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet 397(10278), 952\u2013954 (2021).","journal-title":"Lancet"},{"issue":"15","key":"19936_CR2","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384(15), 1412\u20131423 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10287","key":"19936_CR3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","volume":"397","author":"EJ Haas","year":"2021","unstructured":"Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data. Lancet 397(10287), 1819\u20131829 (2021).","journal-title":"Lancet"},{"issue":"10292","key":"19936_CR4","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1016\/S0140-6736(21)01220-4","volume":"397","author":"M Kosaka","year":"2021","unstructured":"Kosaka, M., Hashimoto, T., Ozaki, A., Tanimoto, T. & Kami, M. Delayed COVID-19 vaccine roll-out in Japan. Lancet 397(10292), 2334\u20132335 (2021).","journal-title":"Lancet"},{"issue":"18","key":"19936_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMc2106757","volume":"385","author":"ASV Shah","year":"2021","unstructured":"Shah, A. S. V. et al. Effect of vaccination on transmission of SARS-CoV-2. N. Engl. J. Med. 385(18), 1718\u20131720 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"19936_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1620\/tjem.2022.J012","volume":"257","author":"T Akaishi","year":"2022","unstructured":"Akaishi, T. et al. Effectiveness of mRNA COVID-19 vaccines in japan during the nationwide pandemic of the delta variant. Tohoku J. Exp. Med. 257(1), 1\u20136 (2022).","journal-title":"Tohoku J. Exp. Med."},{"issue":"7","key":"19936_CR7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","volume":"385","author":"J Lopez Bernal","year":"2021","unstructured":"Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) Variant. N. Engl. J. Med. 385(7), 585\u2013594 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"10269","key":"19936_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","volume":"397","author":"M Voysey","year":"2021","unstructured":"Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269), 99\u2013111 (2021).","journal-title":"Lancet"},{"issue":"4","key":"19936_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12291-021-00968-z","volume":"36","author":"RJ Kaur","year":"2021","unstructured":"Kaur, R. J. et al. Adverse events reported from COVID-19 vaccine trials: A systematic review. Indian J. Clin. Biochem. 36(4), 427\u2013439 (2021).","journal-title":"Indian J. Clin. Biochem."},{"issue":"14","key":"19936_CR10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jama.2021.15072","volume":"326","author":"NP Klein","year":"2021","unstructured":"Klein, N. P. et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 326(14), 1390\u20131399 (2021).","journal-title":"JAMA"},{"issue":"8","key":"19936_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jama.2021.0600","volume":"325","author":"T Shimabukuro","year":"2021","unstructured":"Shimabukuro, T. & Nair, N. Allergic reactions including anaphylaxis after receipt of the first dose of pfizer-BioNTech COVID-19 vaccine. JAMA 325(8), 780\u2013781 (2021).","journal-title":"JAMA"},{"issue":"5","key":"19936_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384(5), 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"19936_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/0973-6247.126690","volume":"8","author":"J Philip","year":"2014","unstructured":"Philip, J., Sarkar, R. S. & Jain, N. A single-centre study of vasovagal reaction in blood donors: Influence of age, sex, donation status, weight, total blood volume and volume of blood collected. Asian J. Transfus. Sci. 8(1), 43\u201346 (2014).","journal-title":"Asian J. Transfus. Sci."},{"key":"19936_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.janxdis.2015.01.009","volume":"31","author":"PT Gilchrist","year":"2015","unstructured":"Gilchrist, P. T., McGovern, G. E., Bekkouche, N., Bacon, S. L. & Ditto, B. The vasovagal response during confrontation with blood-injury-injection stimuli: The role of perceived control. J. Anxiety Disord. 31, 43\u201348 (2015).","journal-title":"J. Anxiety Disord."},{"issue":"4","key":"19936_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5045\/br.2016.51.4.293","volume":"51","author":"JN Seheult","year":"2016","unstructured":"Seheult, J. N., Lund, M. E., Yazer, M. H. & Titlestad, K. Factors associated with vasovagal reactions in apheresis plasma and whole blood donors: A statistical-epidemiological study in a European donor cohort. Blood Res. 51(4), 293\u2013296 (2016).","journal-title":"Blood Res."},{"issue":"1","key":"19936_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.cjca.2019.10.008","volume":"36","author":"AP Deveau","year":"2020","unstructured":"Deveau, A. P. et al. Sex differences in vasovagal syncope: A post hoc analysis of the prevention of syncope trials (POST) I and II. Can. J. Cardiol. 36(1), 79\u201383 (2020).","journal-title":"Can. J. Cardiol."},{"issue":"5","key":"19936_CR17","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1365-2125.2010.03774.x","volume":"71","author":"BY Thong","year":"2011","unstructured":"Thong, B. Y. & Tan, T. C. Epidemiology and risk factors for drug allergy. Br. J. Clin. Pharmacol. 71(5), 684\u2013700 (2011).","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"19936_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker, I. & Prendergast, B. J. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol. Sex Differ. 11(1), 32 (2020).","journal-title":"Biol. Sex Differ."},{"issue":"5","key":"19936_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/ACI.0000000000000568","volume":"19","author":"L Salvati","year":"2019","unstructured":"Salvati, L., Vitiello, G. & Parronchi, P. Gender differences in anaphylaxis. Curr. Opin. Allergy Clin. Immunol. 19(5), 417\u2013424 (2019).","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"15","key":"19936_CR20","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1001\/jama.2021.3976","volume":"325","author":"KG Blumenthal","year":"2021","unstructured":"Blumenthal, K. G. et al. Acute allergic reactions to mRNA COVID-19 vaccines. JAMA 325(15), 1562\u20131565 (2021).","journal-title":"JAMA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19936-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19936-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T12:59:13Z","timestamp":1663246753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-19936-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["19936"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-19936-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15510"}}